| Literature DB >> 27930909 |
Leigh Anderson1, Patrick Antkowiak1, Aden Asefa1, Amber Ballard1, Tushar Bansal1, Ayo Bello1, Bernard Berne1, Kristen Bowsher1, Bennett Blumenkopf1, Ian Broverman1, Mohamad Bydon1, Kuo Chao1, Peter Como1, Karlene Cork1, Ann Costello1, Kathryn De Laurentis1, Angela DeMarco1, Heather Dean1, John Doucet1, Bradley Dworak1, Lisa Epperson1, Eric Franca1, Naz Ghassemian1, Chandramallika Ghosh1, Anupama Govindarajan1, Jay Gupta1, Stacie Gutowski1, Robert Herrmann1, Michael Hoffmann1, William Heetderks1, Steven Hsu1, Daryl Kaufman1, Erin Keegan1, Gregg Kittlesen1, Kevin Khuu1, Hyung Lee1, Larry Lo1, Ian Marcus1, Timothy Marjenin1, Binoy Mathews1, Sanjay Misra1, Vivek Pinto1, Vesper Ramos1, Samuel Raben1, Avena Russell1, Devjani Saha1, Joonil Seog1, Christian Shenouda1, Myra Smith1, Xiaorui Tang1, Kelliann Wachrathit1, Jaime Waterhouse1, Dhanya Williams1, Xiaolin Zheng1, Carlos Peña2.
Abstract
The United States Food and Drug Administration (FDA) ensures that patients in the U.S. have access to safe and effective medical devices. The Division of Neurological and Physical Medicine Devices reviews medical technologies that interface with the nervous system. This article addresses how to navigate the FDA's regulatory landscape to successfully bring medical devices to patients. Published by Elsevier Inc.Entities:
Mesh：
Year: 2016 PMID： 27930909 DOI： 10.1016/j.neuron.2016.10.036
Source DB: PubMed Journal: Neuron ISSN： 0896-6273 Impact factor: 17.173